Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03045315
Other study ID # CHU-303
Secondary ID
Status Recruiting
Phase N/A
First received January 27, 2017
Last updated February 7, 2017
Start date January 2015
Est. completion date August 2019

Study information

Verified date February 2017
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous studies in animal model showed clearly that lipid homeostasis influence oocyte meiosis resumption. However Liver X Receptors pathway has never been investigated in human ovocyte


Description:

In mice deficient of Liver X Receptor (LXR) genes, the oocytes are unable to resume meiosis. Oxysterols are molecules derived from the cholesterol synthesis pathway. They are ligands of the liver X receptors (LXRs). In human, the LXR signalling pathway has never been investigated in this process. The Investigator propose to analyse in granulosa cells surrounding ovocyte the expression of LXR, their target genes and the enzymes involved in oxysterols synthesis. These granulosa cells are normally retrieved and destroyed 18 hours after sperm insemination of oocytes in a In Vitro Fertilization program. The oocyte meiosis resumption will be considered as positive (Granulosa cell positive, GC+) if a zygote is observed 18 hours after sperm insemination and negative (Granulosa cell negative, GC-) if none zygote appears. Moreover the investigator will analyse the quality of embryo development during 5 days after zygote is formed (normal process of In Vitro Fertilization) . The both populations of granulosa cells (GC+ and GC-) will be compared. The measurements of Liver X Receptor genes and the enzymes involved in oxysterols pathways xill be performed by Reverse Transcription-Polymerase Chain Reaction. The accumulation of lipid in granulosa cells will be measures by oil red staining. By this sudy the investigator will probably find new biological markers of resumption meiosis for women enrolled in In Vitro Fertilization programm. Moreover, data will help to better understand the physiopathology of oocyte meiosis failures.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date August 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 36 Years
Eligibility Inclusion Criteria:

- woman aged less 37 years

- included in a IVF program

- tubal infertility

- ovarian stimulation with recombinant FSH

- induced ovulation by recombinant chorionic gonaotrophin

Exclusion Criteria:

- dysovulation

- male infertility

- Ovarian insuficiency

Study Design


Related Conditions & MeSH terms


Intervention

Other:
IVF Procedure


Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Expression of RNAs of LXR pathways in granulosa cells surrounding oocyte The day of the retrieve of granulosa cells, RNA extraction will be performed and the expression of Liver X Receptors genes, their downstream target genes and the enzymes of oxyterols synthesis will be analysed. at day 1
Secondary Accumulation of lipid in granulosa cells surrounding oocyte Embryo development of inseminated ovocytes at day 5 after sperm insemination during In Vitro Fertilization process at day 5
See also
  Status Clinical Trial Phase
Completed NCT06239051 - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting NCT05179993 - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT03737253 - Hormone Evaluation in Artificial Reproductive Technology Phase 4
Not yet recruiting NCT02237755 - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. Phase 2/Phase 3
Not yet recruiting NCT02237781 - Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins Phase 2/Phase 3
Completed NCT01477073 - Multiple Dose FSH-GEX(TM) in Healthy Volunteers Phase 1
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06098495 - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed NCT03998553 - Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women N/A
Completed NCT05189145 - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles N/A
Recruiting NCT05050747 - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed NCT01620346 - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age N/A
Completed NCT00315029 - Patient-Centered Implementation Trial for Single Embryo Transfer N/A
Recruiting NCT03080584 - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients N/A
Not yet recruiting NCT05106712 - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT02328924 - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? Phase 4
Completed NCT01604044 - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial. Phase 1
Completed NCT04019899 - Myo-inositol and Vitamin D3 During IVF N/A